Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
Executive Summary
With the growing problem of antimicrobial resistance putting the spotlight on the need for novel antibiotics, FDA has opened the debate on whether incentives, similar to the orphan drug system, are needed to prompt R&D in the area. But at a recent workshop on the issue, advocacy groups suggested that any such incentives need to be partnered with a more active role on the part of FDA
You may also be interested in...
Financial Incentives Seen As A Path To Resurgence Of Antibiotics
As calls to develop novel antibiotics to treat drug-resistant bacteria grow louder, financial incentives remain a focus in the search for options to stimulate drug discovery
Financial Incentives Seen As A Path To Resurgence Of Antibiotics
As calls to develop novel antibiotics to treat drug-resistant bacteria grow louder, financial incentives remain a focus in the search for options to stimulate drug discovery
Antibiotic Non-Inferiority Trials To Be Addressed By FDA Advisory Committee
Antibiotic drug sponsors may get more clarity on FDA's policy for non-inferiority margins following the conclusion of a three-day Anti-Infective Drugs Advisory Committee meeting in November